Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd

Shanghai Stock Exchange 603707.SS

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Operating Income for the year ending December 31, 2023: USD -46.75 M

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Operating Income is USD -46.75 M for the year ending December 31, 2023, a -127.49% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Operating Income for the year ending December 31, 2022 was USD 170.06 M, a -8.58% change year over year.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Operating Income for the year ending December 31, 2021 was USD 186.01 M, a 38.45% change year over year.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Operating Income for the year ending December 31, 2020 was USD 134.35 M, a 40.14% change year over year.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Operating Income for the year ending December 31, 2019 was USD 95.87 M, a 43.21% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

Shanghai Stock Exchange: 603707.SS

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd

CEO	Ms. Wu Guiping
IPO Date	July 19, 2017
Location	China
Headquarters	1/16 Nanjing Jiangbei New
Employees	1,451
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd manufactures and sells heparin sodium and low molecular weight heparin products for pharmaceutical companies in the People's Republic of China. It offers enoxaparin sodium, dalteparin sodium, and naqu heparin calcium injections. The company also exports its products primarily to the European and American countries. The company was founded in 2000 and is based in Nanjing, the People's Republic of China.

Key trends

Past 5 years